ANI Pharmaceuticals, Inc.
ANIP
$67.36
$0.110.16%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 53.87% | 58.75% | 59.71% | 58.65% | 46.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.87% | 58.75% | 59.71% | 58.65% | 46.38% |
| Cost of Revenue | 31.74% | 21.47% | 17.60% | 22.91% | 36.95% |
| Gross Profit | 70.94% | 92.91% | 102.64% | 95.58% | 54.60% |
| SG&A Expenses | 41.04% | 25.73% | 30.06% | 42.00% | 53.08% |
| Depreciation & Amortization | 4.95% | 5.18% | 8.79% | 12.19% | 20.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.82% | 21.68% | 22.99% | 29.00% | 41.21% |
| Operating Income | 423.00% | 235.22% | 189.48% | 137.50% | 18.30% |
| Income Before Tax | 131.71% | 115.03% | 87.26% | 57.82% | -11.79% |
| Income Tax Expenses | 107.40% | 99.08% | 71.79% | 56.92% | -9.77% |
| Earnings from Continuing Operations | 139.21% | 119.74% | 91.89% | 58.09% | -12.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 139.21% | 119.74% | 91.89% | 58.09% | -12.42% |
| EBIT | 423.00% | 235.22% | 189.48% | 137.50% | 18.30% |
| EBITDA | 146.67% | 582.03% | 859.84% | 602.86% | 55.60% |
| EPS Basic | 127.77% | 111.73% | 88.73% | 61.91% | 5.94% |
| Normalized Basic EPS | 156.04% | 139.61% | 115.78% | 83.16% | -0.43% |
| EPS Diluted | 127.29% | 111.28% | 88.41% | 61.81% | 5.94% |
| Normalized Diluted EPS | 155.44% | 139.33% | 115.65% | 83.10% | -0.43% |
| Average Basic Shares Outstanding | 10.65% | 10.19% | 13.67% | 19.81% | 29.13% |
| Average Diluted Shares Outstanding | 11.83% | 11.06% | 14.19% | 20.06% | 29.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 3.55% | 6.85% | -19.02% | -5.52% | -6.61% |
